Metformin
Treatment for Metabolic Syndrome
Typical Dosage: 500-2000mg daily
Effectiveness
85%
Safety Score
65%
Clinical Trials
173
Participants
400K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
500-2000mg daily
Time to Effect
2-4 weeks for glucose lowering
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$425
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$567
Cost per Remission
$1,700
Metformin Outcomes
for Metabolic Syndrome
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+75%
Remission Rate
+25%
Common Side Effects
Gastrointestinal upset (nausea, diarrhea)
+25%
Vitamin B12 deficiency (long-term)
+7%
Lactic acidosis (rare)
+0.01%
Sources:
Active Clinical Trials
1 active trial recruiting for Metformin in Metabolic Syndrome
Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
NCT06806345RECRUITINGPHASE1, PHASE2
40 participants
INTERVENTIONAL
Cairo, Egypt
Started: Jan 28, 2025
Completed Clinical Trials
12 completed trials for Metformin in Metabolic Syndrome
Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome
NCT02778776COMPLETEDPHASE3
40 participants
INTERVENTIONAL
Guadalajara, Mexico
Started: Jan 1, 2013
Combination of Metformin/Inulin vs Inulin on Adiponectin in Metabolic Syndrome
NCT02773927COMPLETEDPHASE3
40 participants
INTERVENTIONAL
Guadalajara, Mexico
Started: Jan 1, 2013
Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome
NCT01077479COMPLETEDPHASE2
28 participants
INTERVENTIONAL
Sydney, Australia
Started: Feb 1, 2010
The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study
NCT00400231COMPLETEDPHASE2
124 participants
INTERVENTIONAL
Philadelphia, United States
Started: Aug 1, 2005
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
NCT05663749COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Bhubaneswar, India
Started: Sep 20, 2022
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.
NCT00703755COMPLETEDPHASE2
2.29K participants
INTERVENTIONAL
Calgary, Canada +100 more
Started: Mar 1, 2003
Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome
NCT02629627COMPLETEDPHASE2
104 participants
INTERVENTIONAL
Started: Mar 1, 2016
Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome
NCT02960711COMPLETEDPHASE3
1.6K participants
INTERVENTIONAL
Milan, Italy
Started: Feb 1, 2014
Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome
NCT02633488COMPLETEDNA
19 participants
INTERVENTIONAL
Charlottesville, United States
Started: Jun 1, 2014
Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities
NCT02751307COMPLETEDPHASE4
55 participants
INTERVENTIONAL
Started: May 1, 2013
Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome
NCT03355469COMPLETEDPHASE2, PHASE3
91 participants
INTERVENTIONAL
New Brunswick, United States
Started: Aug 7, 2017
Endogenous Opioid Activity and Affective State in Insulin Resistant Women
NCT02069379COMPLETEDPHASE4
42 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Jul 1, 2014
Showing 20 of 173 total trials